5334-04-3

Basic information

• Product Name: 4-chloro-N,N-dimethyl-3-nitrobenzamide
• CAS NO: 5334-04-3
• Molecular Formula: C₉H₉ClN₂O₃
• Molecular Weight: 228.6324
• Mol File: 5334-04-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 389.7°C at 760 mmHg
• Flash Point: 189.5°C
• Density: 1.356g/cm³
• Vapor Pressure: 2.8E-06mmHg at 25°C
• Refractive Index: 1.579
• CAS DataBase Reference: 4-chloro-N,N-dimethyl-3-nitrobenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-N,N-dimethyl-3-nitrobenzamide(5334-04-3)
• EPA Substance Registry System: 4-chloro-N,N-dimethyl-3-nitrobenzamide(5334-04-3)

Safety Data

• Hazardous Substances Data: 5334-04-3(Hazardous Substances Data)

Upstream product

• 124-40-3 dimethyl amine 
• 38818-50-7 4-chloro-3-nitro-benzoyl chloride 
• 96-99-1 4-chloro-3-nitrobenzoate 
• 506-59-2 N,N-dimethylammonium chloride 
• 3282-30-2 pivaloyl chloride 
• 74-11-3 para-chlorobenzoic acid 

Downstream Products

• 1386979-56-1 2-methoxy-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid (2-chloro-5-dimethylcarbamoyl-phenyl)-amide 
• 51919-89-2 3-amino-4-chloro-N,N-dimethylbenzamide 

Relevant articles and documents

PYRIDO PYRIMIDINES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.

AMINE COMPOUNDS

The present invention provide a compound of the formula:wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R1 and R2 are the same or different and each represents a hydrogen atom, etc.; R3 represents a hydrogen atom, etc.; R4 and R5 are the same or different and each represents a hydrogen, etc.; R6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.